Liotir

Liothyronine sodium, the active ingredient in Liotir, is a thyroid hormone presented as an oral dosage form for oral use. It replaces deficient triiodothyronine (T3) in patients with hypothyroidism and related disorders, helping to normalize metabolic activity through systemic hormone replacement therapy.

GNH USA supplies Liotir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other health‑care institutions worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring timely delivery across regulated markets.

Liothyronine sodium acts on the thyroid hormone pathway to treat disorders of thyroid hormone deficiency. - Hypothyroidism: restores normal T3 levels to improve metabolic function. - Myxedema: alleviates severe hypothyroid symptoms by providing rapid hormonal replacement. - Thyroid hormone replacement therapy: maintains euthyroid status in patients requiring T3 supplementation. - Adjunct therapy in thyroid cancer: supports thyroid hormone balance after thyroidectomy or radioactive iodine treatment. - Depression associated with hypothyroidism: improves mood and cognitive symptoms linked to low thyroid hormone.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Palpitations: sensation of rapid or irregular heartbeat. - Tremor: fine shaking of the hands or limbs. - Anxiety or nervousness: heightened emotional response. - Heat intolerance: increased sensitivity to warm environments. - Diarrhea: loose or frequent stools. - Weight loss: unintended reduction in body weight.

Serious or Rare Side Effects: - Cardiac arrhythmias: potentially life‑threatening irregular heart rhythms. - Angina or myocardial ischemia: chest pain due to reduced heart blood flow. - Osteoporosis or bone demineralization: increased risk of fractures with long‑term use. - Hyperthyroid crisis (thyrotoxicosis): severe excess of thyroid hormone symptoms. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Hepatic dysfunction: abnormal liver enzyme elevations.

Before initiating therapy, consider patient‑specific factors and monitor for adverse outcomes. - Dose adjustment: tailor dose based on serum T3 levels and clinical response. - Cardiovascular monitoring: assess heart rate, rhythm, and blood pressure, especially in patients with cardiac disease. - Bone health: evaluate risk of osteoporosis in long‑term therapy, particularly in postmenopausal women. - Pregnancy and lactation: use only if benefits outweigh potential risks; consult obstetric guidance. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Liothyronine sodium may interact with several medications, altering its efficacy or safety.

Major Interactions (Avoid): - Antithyroid drugs (e.g., methimazole, propylthiouracil): antagonize thyroid hormone action. - Beta‑blockers (high doses): may mask tachycardia symptoms. - Corticosteroids (high dose): increase metabolism of thyroid hormones, reducing effectiveness.

Moderate Interactions (Monitor Closely): - Oral contraceptives and estrogen therapy: may increase thyroid‑binding globulin, altering hormone levels. - Anticoagulants (warfarin): thyroid hormone can enhance anticoagulant effect, requiring INR monitoring. - Diuretics (loop, thiazide): may affect electrolyte balance and potentiate cardiac effects.